Comments
Loading...
Orientación y previsiones
Teva Pharmaceutical Indus emite una orientación sobre las ganancias por acción y los ingresos futuros, lo que ofrece a los inversores una idea de cuánto espera ganar la empresa en los próximos períodos.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
07/30/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.50 | $2.60 | $2.50 | $16.80B | $17.20B | $16.97B | |
05/07/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.45 | $2.65 | $2.56 | $16.80B | $17.20B | $17.24B | |
03/27/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.35 | $2.65 | $2.54 | $16.80B | $17.40B | $17.14B | |
03/27/2025 | TEVA | Teva Pharmaceutical Indus | Q1 | 2025 | $0.52 | $0.52 | $0.48 | $3.99B | $3.99B | $3.98B | |
01/29/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.35 | $2.65 | $2.78 | $16.80B | $17.40B | $17.09B | |
11/06/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.40 | $2.50 | $2.45 | $16.10B | $16.50B | $16.26B | |
07/31/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.30 | $2.50 | $2.34 | $16.00B | $16.40B | $16.01B | |
05/08/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.20 | $2.50 | $2.41 | $15.70B | $16.30B | $15.86B | |
01/31/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.20 | $2.50 | $2.42 | $15.70B | $16.30B | $15.57B | |
11/08/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.28 | $15.10B | $15.50B | $15.14B | |
08/02/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.27 | $15.00B | $15.40B | $15.02B | |
05/10/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.40 | $14.80B | $15.40B | $15.06B | |
02/08/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.52 | $14.80B | $15.40B | $15.23B | |
11/03/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | $2.50 | $14.80B | $15.40B | $15.46B | |
07/26/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | — | $15.00B | $15.60B | $15.67B | |
05/03/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | $2.51 | $15.40B | $16.00B | $15.97B | |
02/09/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | $2.64 | $15.60B | $16.20B | $16.32B | |
10/27/2021 | TEVA | Teva Pharmaceutical Indus | FY | 2021 | $2.50 | $2.70 | $2.58 | $16.00B | $16.40B | $16.30B | |
07/28/2021 | TEVA | Teva Pharmaceutical Indus | FY | 2021 | $2.50 | $2.70 | $2.45 | $16.00B | $16.40B | $16.55B | |
04/28/2021 | TEVA | Teva Pharmaceutical Indus | FY | 2021 | $2.50 | $2.70 | $2.61 | $16.40B | $16.80B | $16.68B | |
02/10/2021 | TEVA | Teva Pharmaceutical Indus | FY | 2021 | $2.50 | $2.70 | $2.63 | $16.40B | $16.80B | $16.76B |
PREGUNTAS FRECUENTES
¿Cuál es la orientación más reciente de Teva Pharmaceutical Indus (TEVA)?
La orientación más reciente para Teva Pharmaceutical Indus (TEVA) se informó el julio 30, 2025 para el año completo 2025. La empresa proporcionó una guía de ganancias por acción en el rango de $2.50 a $2.60, en comparación con el EPS estimado de $2.50. Además, Teva Pharmaceutical Indus pronosticó ingresos entre $16.80B y $17.20B para el trimestre.
Explora orientación y previsión sobre todos los valores.